A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2014
At a glance
- Drugs AZD 2423 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 24 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.